All XRAYs

20 March 2023

Study : New oral drug treatment for some advanced breast cancer

Most relevant for: People with HR-positive, HER2-negative advanced breast cancer

The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)

Este artículo está disponible en español.

11 March 2023

Study : Systemic racism may delay breast biopsy for Black and Asian people

Most relevant for: People who have had an abnormal mammogram

Black and Asian people are more likely to have to wait more than 90 days between an abnormal mammogram and a biopsy compared to white people. After accounting for other factors, the authors conclude that these disparities may be due to systemic racism. (Posted 3/8/23)

Este artículo está disponible en español.

1 March 2023

Study : Promising early results for treating metastatic prostate cancer

Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)

The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)

Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage. 

Este artículo está disponible en español.

27 February 2023

Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people

Most relevant for: People with early-stage breast cancer who are post-menopausal

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

24 February 2023

Study : Increasing soy in your diet may lower your cancer risk

Most relevant for: People interested in reducing cancer risk

This study looked at a link between a diet rich in soy and cancer risk. With the addition of more recent literature, this study suggests that soy lowers the risk of cancer in the general population. (Posted 2/24/23)

Este artículo está disponible en español.

22 February 2023

Study : Frequent aspirin use may reduce the risk of ovarian cancer

Most relevant for: Healthy people at high-risk of ovarian cancer.

Aspirin may help lower the risk of ovarian cancer in people who have a high risk of the disease, according to a new analysis of 17 studies. While other preventive strategies have been found to more effectively lower the likelihood of developing ovarian cancer in high-risk women, taking aspirin daily or almost daily may reduce a person’s risk of developing ovarian cancer by 13 percent. The benefit was greater among people with additional risk factors for the disease. (Posted 2/22/23)

Este artículo está disponible en español.

3 February 2023

Study : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer

Most relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic  breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

9 January 2023

Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations

Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.

3 January 2023

Study : What influences aggressive end-of-life care for ovarian cancer?

Most relevant for: People with advanced ovarian cancer

Aggressive medical treatment is often given to people with terminal ovarian cancer when prior treatment has stopped working. This aggressive end-of-life treatment conflicts with clinical guidelines, may increase pain and suffering and does not extend life. This study found that the end-of-life care that a person with ovarian cancer receives is influenced by their doctors. (Posted 1/3/23)

Este artículo está disponible en español.

22 December 2022

Study : Male breast cancer: Patient and surgeon experiences

Most relevant for: Men with breast cancer

By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)

Este artículo está disponible en español.